From: Gemcitabine-induced cardiomyopathy: a case report and review of the literature
Author | Demography | Dose of gemcitabine | Duration of treatment | Side effect | History of CAD | Timing | Outcome | Probability |
---|---|---|---|---|---|---|---|---|
Ozturk et al.[17] | 59F with metastatic leiomyosarcoma | 900mg/m2 | 8 days | Coronary vasospasm | Yes | 30 minutes after infusion | Survived. Gemcitabine therapy stopped | Strong |
Bdair et al . [18] | 43F with metastatic NSCLC | 1000mg/m2 | 7 weeks | NSTEMI VT | Yes | 3 days after infusion | Survived. Gemcitabine therapy stopped | Weak |
Kalapura et al . [19] | 54M with metastatic pancreatic cancer | 1900mg | 5th cycle | NSTEMI | No CAD, no risk factors | 6 hours after infusion | Survived. Recurrent symptoms with 7th cycle | Strong |
Tayer-Shifman et al.[20] | 67F with metastatic ductal carcinoma of breast | 1000-1400mg/m2 | 3rd cycle | SVT/AVNRT | No CAD, no risk factors | Hours after infusion | Survived. Gemcitabine therapy stopped | Strong |
Santini et al.[21] | 78M with pancreatic adenocarcinoma | NK | 1st cycle | AF | History of AF in the past | 18-22 hours after the infusion | Survived 6 total episodes of AF 18-22 hours after the infusion | Strong |
Ferrari et al.[22] | 72F with metastatic lung adenocarcinoma | 1200mg/m2 | 1st cycle | AF | No history of AF | 18 hours after the infusion | Survived 3 total episodes of AF each after 18 hours of infusion | Strong |
Ferrari et al.[22] | 73F with NSCLC | 1200mg/m2 | 3rd cycle | AF | No history of AF | 12 hours after the infusion | Survived. Gemcitabine stopped | Strong |
Tavil et al.[23] | 65M with NSCLC | 1200mg/m2 | 2nd cycle | AF | No history of AF | 7 hours after the infusion | Gemcitabine stopped | Strong |
Ciotti et al.[24] | 70M with metastatic pancreatic adenocarcinoma | NK | 1st cycle | AF | No history of AF | 6 days after the infusion | AF recurred with further therapy | Strong |
Yajima et al.[25] | 82F with advanced pancreatic carcinoma | 16, 800mg-total dose | Two years of treatment | HF | NK | 2 years | Gemcitabine stopped | Weak |
Khan et al. [present case] | 56M with pancreatic adenocarcinoma | 1000mg/m2 | Two cycles (2 months) | CMP/HF | No prior history of CHF/CAD | 2 months | Gemcitabine stopped, partial recovery | Strong |